Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

Phase 3

Completed

Conditions: Neovascular Age-Related Macular Degeneration

Interventions: Drug: Brolucizumab 6mg
Drug: Aflibercept 2 mg

First Posted Date: 2019-08-06

Last Posted Date: 2024-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 397

Registration Number: NCT04047472

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

Phase 2

Terminated

Conditions: Sjögren Syndrome

Interventions: Drug: Remibrutinib
Drug: Placebo

First Posted Date: 2019-07-29

Last Posted Date: 2023-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 73

Registration Number: NCT04035668

Locations: 🇬🇧
Novartis Investigative Site, Tyne And Wear, United Kingdom

Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC

Phase 4

Active, not recruiting

Conditions: Heart Failure
Chagas Disease

Interventions: Drug: Enalapril
Drug: Sacubitril/valsartan

First Posted Date: 2019-07-17

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 919

Registration Number: NCT04023227

Locations: 🇲🇽
Novartis Investigative Site, Xalapa, Mexico

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

Phase 3

Active, not recruiting

Conditions: Cardiovascular Disease and Lipoprotein(a)

Interventions: Drug: TQJ230
Drug: Placebo

First Posted Date: 2019-07-17

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 8323

Registration Number: NCT04023552

Locations: 🇺🇸
SEC Clinical Research LLC, Andalusia, Alabama, United States
🇺🇸
University of California San Diego, San Diego, California, United States
🇺🇸
UCSF, San Francisco, California, United States

and more 31 locations

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

Phase 3

Completed

Conditions: Age-related Macular Degeneration

Interventions: Biological: Aflibercept 2 mg
Biological: Brolucizumab 6 mg

First Posted Date: 2019-07-02

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 734

Registration Number: NCT04005352

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Phase 1

Terminated

Conditions: Colorectal Cancer
Head and Neck Squamous Cell Carcinoma
Gastrointestinal Stromal Tumors
Esophageal SCC
Non-small Cell Lung Carcinoma

Interventions: Drug: TNO155
Drug: Spartalizumab
Drug: Ribociclib

First Posted Date: 2019-06-27

Last Posted Date: 2024-11-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 122

Registration Number: NCT04000529

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇪🇸
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain

Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.

Phase 2

Withdrawn

Conditions: Bronchial Asthma
Asthma
Asthma, Bronchial
Eosinophilia
Physiological Effects of Drugs

Interventions: Drug: QAW039

First Posted Date: 2019-06-18

Last Posted Date: 2020-05-14

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03989635

Study to Assess the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.

Phase 2

Completed

Conditions: Aplastic Anemia

Interventions: Drug: Eltrombopag 25 mg

First Posted Date: 2019-06-17

Last Posted Date: 2023-11-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT03988608

Locations: 🇨🇳
Novartis Investigative Site, Tianjin, China

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Phase 3

Completed

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)

Interventions: Drug: valsartan
Drug: sacubitril/valsartan
Drug: valsartan matching placebo
Drug: sacubitril/valsartan matching placebo

First Posted Date: 2019-06-17

Last Posted Date: 2024-07-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 467

Registration Number: NCT03988634

Locations: 🇺🇸
Boston Univeristy Medical Center ., Boston, Massachusetts, United States
🇺🇸
Colorado Heart and Vascular ., Lakewood, Colorado, United States
🇺🇸
Swedish Medical Ctr Cardiovascular Re, Seattle, Washington, United States

and more 83 locations

A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients

Phase 4

Completed

Conditions: Migraine Disorders

Interventions: Drug: placebo
Drug: erenumab

First Posted Date: 2019-06-06

Last Posted Date: 2021-08-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT03977649

Locations: 🇮🇹
Novartis Investigative Site, Napoli, Italy

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy